EditorialRegulatory T cells: From bench to bedside
Introduction
In the past decade several subsets of regulatory T cells (Tregs) have been described in both human and rodents [1]. Among them are naturally occurring CD4+CD25+ Tregs. The importance of this population of Tregs in the control of autoimmunity was first demonstrated by Sakaguchi et al. in 1995 [2]. They showed that the spontaneous development of autoimmune disease in thymectomised neonate mice could be prevented by the adoptive transfer of CD4+CD25+ T cells from normal mice [2]. Subsequent studies have showed that transcript factor Foxp3 gene appears to play a key role in the ontogeny of CD4+CD25+ Tregs [3], [4]. Mutation of Foxp3 gene in human causes the IPEX syndrome [5]. Now it is clear that Tregs are the key regulators for the control of all immune responses including autoimmunity, tumor immunity, infection, allergic reaction and transplantation tolerance, and their translation to the clinic would lead to cure many forms of human diseases [1]. In October 2008, an international conference held in Beijing, China (China Tregs 2008) was dedicated entirely to the latest progress in the biology of Tregs including their development, function, mechanism of action, and homeostasis, and their clinical application in human diseases [6].
Section snippets
Foxp3 biochemistry and the development, homeostasis, stability and function of Tregs
Foxp3 is key regulator for Treg function and homeostasis. In this Special Issue of China Tregs 2008, Zhou et al. from University of Pennsylvania (USA) summarized their recent data on the structure and the ensemble of Foxp3 transcription factor. The crystal structure of Foxp3 revealed that Foxp3 oligomerization domain as an anti-parallel coiled coil with a potential to mediate high-order homo or hetero oligomerization. The homo-oligomerization of Foxp3 would promote proper organization of the
Treg therapy in autoimmunity, cancer, and transplantation tolerance
Naïve CD4+ T cells are able to differentiate into either Tregs (induced Tregs: iTregs) or IL-17 producing effector Th17 cells under immunosuppressive milieu of TGF-b or inflammatory condition of TGF-b and IL-6. In this Special Issue of China Tregs 2008, Huter et al. from National Institutes of Health (NIH, USA) demonstrated that antigen-specific iTregs were more potent than polyclonal iTregs in inhibiting Th17-mediated autoimmune gastritis, and polyclonal nTreg had no effect. Their data are in
Preclinical studies of Tregs in primates and in patients
It has been showed that CD4+CD25+ Tregs have impaired suppressive function in multiple sclerosis (MS) patients [12]. In this issue, Ma et al. from University of Montréal (Canada) studied the number and function of Tregs in a mimic model of human MS in Cynomolgus Monkeys. They found that dysfunction of CD4+CD25+ Tregs and IL-10 producing type 1 regulatory T cells (Tr1 cells) contributed to the pathogenesis of the disease, and adoptive transfer of Tregs would be a clinical applicable strategy to
Conclusion
At China Tregs 2008, more than 60 of world's most renowned Treg experts gave the sought-after plenary presentations on the biology of Tregs and its clinical application in human diseases. Further 40 plenary oral presentations and 200 abstracts were also presented at the conference. The presentations of world's most senior speakers have been featured in the recently published textbook “Regulatory T cells and Clinical Application” (Springer, New York), edited by Shuiping Jiang [1], and in the
References (12)
- et al.
In vitro-expanded donor alloantigen-specific CD4+CD25+ regulatory T cells promote experimental transplantation tolerance
Blood
(Jan 15 2007) - et al.
Induction of allopeptide-specific human CD4+CD25+ regulatory T cells ex vivo
Blood
(Sep 15 2003) - et al.
Immunologic self-tolerance maintained by activated T cells expressing Il-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases
J Immunol
(1995) - et al.
Control of regulatory T cell development by the transcription factor Foxp3
Science
(2003) - et al.
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells
Nat Immunol
(2003)
Cited by (4)
CD4 + CD25 + regulatory T cells in tumor immunity
2016, International ImmunopharmacologyCitation Excerpt :Tregs arise in the thymus, represent 5% to 10% of CD4 + T cells in the periphery, and constitutively express the IL-2 receptor (IL-2R) α chain (CD25), cytotoxic T lymphocyte–associated antigen 4 (CTLA-4), and glucocorticoid-induced TNF receptor family-related gene (GITR) [3–4]. Tregs as important regulators of basic processes that are designed to maintain tolerance has opened an important area of potential clinical investigation in autoimmunity, allergy, inflammation graft-versus-host disease and transplantation [5–11]. Organ transplantation results in the activation of both innate and adaptive immune responses to the foreign antigens.
Tregalizumab – A Monoclonal Antibody to Target Regulatory T Cells
2016, Frontiers in ImmunologyThe impact of biological therapy on regulatory T cells in rheumatoid arthritis
2014, Rheumatology (United Kingdom)CD4<sup>+</sup>CD25<sup>+</sup>but not CD4<sup>+</sup>Foxp3<sup>+</sup> T cells as a regulatory subset in primary biliary cirrhosis
2010, Cellular and Molecular Immunology